Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CMPS 
Compass Pathways Plc (CMPS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CMPS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14.9
1 Year Target Price $14.9
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.49% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 489.30M USD | Price to earnings Ratio - | 1Y Target Price 14.9 |
Price to earnings Ratio - | 1Y Target Price 14.9 | ||
Volume (30-day avg) 11 | Beta 2.18 | 52 Weeks Range 2.25 - 7.53 | Updated Date 09/17/2025 |
52 Weeks Range 2.25 - 7.53 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.36% | Return on Equity (TTM) -71.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 302707446 | Price to Sales(TTM) - |
Enterprise Value 302707446 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.51 | Shares Outstanding 95941296 | Shares Floating 58413839 |
Shares Outstanding 95941296 | Shares Floating 58413839 | ||
Percent Insiders 13.3 | Percent Institutions 55.63 |
Upturn AI SWOT
Compass Pathways Plc
Company Overview
History and Background
Compass Pathways Plc was founded in 2016. It is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. They are primarily focused on developing psilocybin therapy for treatment-resistant depression (TRD) and other mental health disorders.
Core Business Areas
- Pharmaceutical Development: Developing COMP360 psilocybin therapy and conducting clinical trials to demonstrate its safety and efficacy for treatment-resistant depression (TRD) and other mental health conditions.
- Digital Therapeutics: Integrating digital technologies into their therapeutic programs to enhance patient outcomes and accessibility.
- Patient Access: Working on strategies to ensure patients have access to their therapies once approved, including market access, reimbursement, and patient support programs.
Leadership and Structure
The leadership team includes Kabir Nath (CEO), Guy Goodwin (Chief Medical Officer), and Greg Weaver (CFO). The company has a Board of Directors that oversees its operations and strategy.
Top Products and Market Share
Key Offerings
- COMP360 psilocybin therapy: COMP360 is Compass Pathways' lead investigational drug. It is a proprietary formulation of psilocybin, a psychedelic compound, intended for use in conjunction with psychological support from specially trained therapists. As this is an investigational product, there is no current revenue or market share data. Competitors include companies developing similar psilocybin-assisted therapies and existing pharmaceutical treatments for depression.
Market Dynamics
Industry Overview
The mental health market is large and growing, with a significant unmet need for effective treatments for conditions like treatment-resistant depression. There is increasing interest and investment in psychedelic-assisted therapies as potential breakthrough treatments.
Positioning
Compass Pathways is a leading company in the development of psilocybin therapy for mental health disorders. They are pioneering clinical trials and regulatory pathways for this novel treatment approach. They are well positioned to address unmet need in the field.
Total Addressable Market (TAM)
The TAM for mental health treatments is very large, estimated to be worth billions of dollars annually. Depression is a major contributor. Compass Pathways aims to capture a significant portion of this TAM with their innovative approach to treatment-resistant depression (TRD).
Upturn SWOT Analysis
Strengths
- First-mover advantage in psilocybin therapy development
- Strong intellectual property portfolio
- Experienced leadership team
- Positive clinical trial results to date
- Significant funding and partnerships
Weaknesses
- Reliance on a single lead product candidate (COMP360)
- Regulatory uncertainty surrounding psychedelic therapies
- High development costs associated with clinical trials
- Potential for adverse effects associated with psilocybin
- Limited commercialization experience to date
Opportunities
- Expansion of COMP360 to treat other mental health conditions
- Partnerships with healthcare providers and payers
- Advancements in digital therapeutics to enhance treatment outcomes
- Increased public awareness and acceptance of psychedelic therapies
- Regulatory approvals in multiple countries
Threats
- Competition from other companies developing psychedelic therapies
- Changes in regulatory landscape or public perception
- Unfavorable clinical trial results
- Pricing and reimbursement challenges
- Generic competition if intellectual property is not adequately protected
Competitors and Market Share
Key Competitors
- GHRS
- ATAI
- MNMD
Competitive Landscape
Compass Pathways has a first-mover advantage. However, other companies are actively developing psychedelic therapies. The competitive landscape is evolving rapidly, and success will depend on clinical trial results, regulatory approvals, and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is mainly related to expansion of operations, fundraising and clinical trial progress.
Future Projections: Future growth is contingent upon successful clinical trial outcomes, regulatory approvals, and commercialization of COMP360. Analyst estimates vary widely depending on assumptions about these factors.
Recent Initiatives: Recent strategic initiatives include advancing COMP360 through Phase III clinical trials, expanding the company's intellectual property portfolio, and engaging with regulatory agencies.
Summary
Compass Pathways is a pioneering company in the psilocybin therapy space, targeting treatment-resistant depression. Its success hinges on the outcome of ongoing Phase III clinical trials for COMP360. While it holds a leading position and strong IP, regulatory uncertainties and competition pose risks. It needs to focus on its trials and get them approved to prove the legitimacy of its product and the broader psychedelics industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports and filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available estimates. The AI-based rating is for illustrative purposes only and should not be the sole basis for investment decisions. The psychedelic industry is highly volatile.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Pathways Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-18 | CEO & Director Mr. Kabir Kumar Nath M.A., M.B.A. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 166 | Website https://compasspathways.com |
Full time employees 166 | Website https://compasspathways.com | ||
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.